Top

International Journal of Colorectal Disease

Published in:

01-11-2016 | Original Article

Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn’s disease following ileocolonic resection

Authors: Yi Li, Luca Stocchi, Yuanyi Rui, Feza H. Remzi, Bo Shen

Published in: International Journal of Colorectal Disease | Issue 11/2016

Abstract

Purpose

There are no published data or guidelines on whether the same anti-tumor-necrosis factor (TNF) agents used preoperatively or different anti-TNF agents are preferable to treat postoperative recurrence. Our aim was to compare the efficacy of the consistent vs. switched anti-TNF approaches in patients with recurrent Crohn’s disease (CD) after their inception ileocolonic resection (ICR).

Methods

Patients with CD receiving anti-TNF agents before the inception ICR who were treated for clinical recurrence with the same or different anti-TNF agents after surgical resection were included in the study. The outcome of the study was the need for the subsequent resection of ileocolonic anastomosis (ICA) as calculated with survival curves.

Results

Eighty-five patients were included in the study. The mean age of the whole cohort at the inception ICR was 35.1 ± 13.5 years. The whole cohort consisted 42 (49.4 %) in the consistent group and 43 (50.6 %) in the switched group. No significant differences were observed in demographic and clinical variables between the two groups. During the median follow-up of 1.5 (interquartile range, 0.8–3.1) years, seven (16.7 %) patients in the consistent group and eight (18.6 %) in the switched group required the repeat resection of ICA. Similar results were found in terms of the subsequent resection of ICA-free survival (hazard ratio = 1.36, 95 % confidence interval 0.49–3.76, P = 0.54) between the consistent and switched groups.

Conclusions

The adherence to the same anti-TNF agent appeared to be as effective as the switching approach to different anti-TNF agent in treating postoperative recurrent CD after the inception ICR.

Papadakis KA, Targan SR (2000) Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119(4):1148–1157CrossRefPubMed

Van Deventer SJ (1997) Tumour necrosis factor and Crohn's disease. Gut 40(4):443–448CrossRefPubMedPubMedCentral

Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349(9051):521–524CrossRefPubMed

Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK (2014) Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Aliment Pharmacol Ther 39(12):1349–1362. doi:10.1111/apt.12749 CrossRefPubMed

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 337(15):1029–1035. doi:10.1056/NEJM199710093371502 CrossRefPubMed

Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549. doi:10.1016/S0140-6736(02)08512-4 CrossRefPubMed

Ricart E, Sandborn WJ (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. Gastroenterology 117(5):1247–1248CrossRefPubMed

Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340(18):1398–1405. doi:10.1056/NEJM199905063401804 CrossRefPubMed

Akobeng AA, Sandborn WJ, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG (2014) Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? Inflamm Bowel Dis 20(11):2132–2141. doi:10.1097/MIB.0000000000000218 CrossRefPubMed

10.

Su CG, Lichtenstein GR (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Gastroenterology 125(5):1544–1546CrossRefPubMed

11.

Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348(7):601–608. doi:10.1056/NEJMoa020888 CrossRefPubMed

12.

Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124(4):917–924. doi:10.1053/gast.2003.50145 CrossRefPubMed

13.

Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2(7):542–553CrossRefPubMed

14.

Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98(6):1315–1324. doi:10.1111/j.1572-0241.2003.07457.x CrossRefPubMed

15.

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460–1468. doi:10.1001/jama.2011.406 CrossRefPubMed

16.

Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM (2012) Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 18(2):349–358. doi:10.1002/ibd.21831 CrossRefPubMed

17.

Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF (2007) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146(12):829–838CrossRefPubMed

18.

Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P (2010) Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 8(8):688–695 e682. doi:10.1016/j.cgh.2010.04.021 CrossRefPubMed

19.

Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S (2014) Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147(3):618–627 e613. doi:10.1053/j.gastro.2014.05.008 CrossRefPubMed

20.

de Silva PS, Nguyen DD, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan AN (2012) Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther 36(5):459–466. doi:10.1111/j.1365-2036.2012.05214.x CrossRefPubMed

21.

Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P (2012) Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 61(2):229–234. doi:10.1136/gutjnl-2011-300755 CrossRefPubMed

22.

Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L (2012) Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther 35(6):625–633. doi:10.1111/j.1365-2036.2012.05002.x CrossRefPubMed

23.

Lemann M (2006) Review article: can post-operative recurrence in Crohn's disease be prevented? Aliment Pharmacol Ther 24(Suppl 3):22–28. doi:10.1111/j.1365-2036.2006.03055.x CrossRefPubMed

24.

Rutgeerts P (2006) Review article: recurrence of Crohn's disease after surgery—the need for treatment of new lesions. Aliment Pharmacol Ther 24(Suppl 3):29–32. doi:10.1111/j.1365-2036.2006.03056.x CrossRefPubMed

25.

Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6):749–753. doi:10.1136/gut.2005.082909 CrossRefPubMedPubMedCentral

26.

Sokol H, Polin V, Lavergne-Slove A, Panis Y, Treton X, Dray X, Bouhnik Y, Valleur P, Marteau P (2009) Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease. Gut 58(9):1218–1225. doi:10.1136/gut.2009.177782 CrossRefPubMed

27.

Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR (2001) An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120(6):1330–1338CrossRefPubMed

28.

Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S (2007) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357(3):228–238. doi:10.1056/NEJMoa067594 CrossRefPubMed

29.

Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53(10):1485–1493. doi:10.1136/gut.2003.035253 CrossRefPubMedPubMedCentral

30.

Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF (2008) Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6(6):644–653. doi:10.1016/j.cgh.2008.03.014 CrossRefPubMed

31.

Hanauer SB (2004) Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord 4(Suppl 3):S18–S24PubMed

32.

Nanda KS, Cheifetz AS, Moss AC (2013) Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 108(1):40–47 . doi:10.1038/ajg.2012.363quiz 48CrossRefPubMed

33.

Ordas I, Feagan BG, Sandborn WJ (2012) Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 10(10):1079–1087 . doi:10.1016/j.cgh.2012.06.032quiz e1085-1076CrossRefPubMed

34.

Miheller P, Kiss LS, Lorinczy K, Lakatos PL (2012) Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opin Biol Ther 12(2):179–192. doi:10.1517/14712598.2012.644271 CrossRefPubMed

35.

Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE (2009) Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136(2):441–450 e441 . doi:10.1053/j.gastro.2008.10.051quiz 716CrossRefPubMed

Title: Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn’s disease following ileocolonic resection
Authors: Yi Li
Luca Stocchi
Yuanyi Rui
Feza H. Remzi
Bo Shen
Publication date: 01-11-2016
Publisher: Springer Berlin Heidelberg
Published in: International Journal of Colorectal Disease / Issue 11/2016
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-016-2632-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn’s disease following ileocolonic resection

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2016

Phantom rectal sensations following abdominoperineal excision of the rectum (APER) and vertical rectus abdominis myocutaneous (VRAM) flap perineal reconstruction

Preoperative vitamin C supplementation improves colorectal anastomotic healing and biochemical parameters in malnourished rats

Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis

Erratum to: Different site, different clinical outcomes in perforated colorectal cancer?

Differences in surgical site infection between laparoscopic colon and rectal surgeries: sub-analysis of a multicenter randomized controlled trial (Japan-Multinational Trial Organization PREV 07-01)

Tumor characteristics associated with malignant large bowel obstruction in stage IV colorectal cancer patients undergoing chemotherapy